# Provocative Research Questions for Prof. Ugur SEZERMAN
## Using Verbalized Sampling to Identify Research Gaps, Contradictions & Synergies

**ìƒì„±ì¼**: 2025-11-10
**ë°©ë²•ë¡ **: Verbalized Sampling (VS) - í™•ë¥  ë¶„í¬ ê¸°ë°˜ ì°½ì˜ì  ì§ˆë¬¸ ìƒì„±
**ëª©í‘œ**: ë»”í•œ ì§ˆë¬¸ íƒˆí”¼, ì—°êµ¬ ê³µë°± ë° ë„ë°œì  ì‹œë„ˆì§€ ë°œêµ´

---

## ğŸ¯ Verbalized Sampling ë°©ë²•ë¡  ì ìš©

### í•µì‹¬ ì›ë¦¬
1. **Mode Collapse íšŒí”¼**: ìµìˆ™í•˜ê³  ì•ˆì „í•œ ì§ˆë¬¸ ëŒ€ì‹  ë‹¤ì–‘í•œ ê°ë„ íƒìƒ‰
2. **í™•ë¥  ë¶„í¬ ëª…ì‹œ**: ê° ì§ˆë¬¸ì˜ ë…ì°½ì„±/ì¤‘ìš”ë„ë¥¼ í™•ë¥ ë¡œ í‘œí˜„
3. **Typicality Bias ê·¹ë³µ**: ì¸ì§€ì  í¸í–¥(ìµìˆ™í•œ ê²ƒ ì„ í˜¸)ì„ ì˜ë„ì ìœ¼ë¡œ ìš°íšŒ
4. **ì—°êµ¬ ê³µë°± ì§‘ì¤‘**: Unexplored intersections, contradictions, hidden assumptions

---

## ğŸ”¥ Category 1: Paradoxes & Contradictions (ì—­ì„¤ê³¼ ëª¨ìˆœ)

### Question Set A: "The AMR Evolution Paradox"

**Context**: SEZERMANì€ ISS ì—°êµ¬ì—ì„œ "ê·¹í•œ í™˜ê²½ â†’ AMR ê°€ì†í™”"ë¥¼ ë°œê²¬í–ˆì§€ë§Œ, Urban microbiome ì—°êµ¬ëŠ” "ë‹¤ì–‘ì„± â†‘ â†’ AMR resilience â†‘"ë¥¼ ì‹œì‚¬í•©ë‹ˆë‹¤.

**5 Provocative Questions with Probabilities:**

1. **[30% probability]** "ë‹¹ì‹ ì˜ ISS ì—°êµ¬ëŠ” ê·¹í•œ í™˜ê²½ì´ AMRì„ ê°€ì†í™”í•œë‹¤ê³  í–ˆì§€ë§Œ, ë™ì‹œì— ë„ì‹œ ë¯¸ìƒë¬¼ ë‹¤ì–‘ì„±ì´ ë†’ì„ìˆ˜ë¡ AMR resilienceê°€ ì»¤ì§„ë‹¤ëŠ” ì¦ê±°ë„ ìˆìŠµë‹ˆë‹¤. ì´ ë‘ ë°œê²¬ì€ ëª¨ìˆœì²˜ëŸ¼ ë³´ì´ëŠ”ë°, **í˜¹ì‹œ 'ì ì ˆí•œ ìˆ˜ì¤€ì˜ ìŠ¤íŠ¸ë ˆìŠ¤'ê°€ AMRì„ ì–µì œí•˜ëŠ” sweet spotì´ ì¡´ì¬í•˜ë‚˜ìš”?** ì¦‰, too little stress (commensal environment) = vulnerable, optimal stress (diverse urban) = resilient, extreme stress (ISS/ICU) = AMR explosion? ì´ U-shaped curveë¥¼ ì •ëŸ‰í™”í•œ ì ì´ ìˆë‚˜ìš”?"

2. **[25% probability]** "ISSì˜ ê·¹í•œ í™˜ê²½ê³¼ ICUì˜ í•­ìƒì œ ì••ë ¥ì„ ë¹„êµí•˜ì…¨ëŠ”ë°, **ì—­ìœ¼ë¡œ ìƒê°í•´ë³´ë©´ ISSì—ëŠ” í•­ìƒì œê°€ ì—†ëŠ”ë°ë„ AMR ìœ ì „ìê°€ ì¦ê°€í–ˆë‹¤ëŠ” ê±´, AMRì´ ì›ë˜ 'í•­ìƒì œ ëŒ€ì‘'ì´ ì•„ë‹ˆë¼ 'ì¼ë°˜ ìŠ¤íŠ¸ë ˆìŠ¤ ëŒ€ì‘'ì˜ ë¶€ì‚°ë¬¼ì¼ ê°€ëŠ¥ì„±**ì„ ì‹œì‚¬í•˜ì§€ ì•Šë‚˜ìš”? ê·¸ë ‡ë‹¤ë©´ ìš°ë¦¬ê°€ AMRì„ ì˜ëª» ì´í•´í•˜ê³  ìˆëŠ” ê±´ ì•„ë‹ê¹Œìš”? 'Antimicrobial Resistance'ê°€ ì•„ë‹ˆë¼ 'Adaptive Stress Resilience'ë¡œ ì¬ê°œë…í™”í•´ì•¼ í•˜ëŠ” ê±´ ì•„ë‹Œì§€?"

3. **[20% probability]** "ë³‘ì› AMR cartographyì—ì„œ ICUê°€ ê°€ì¥ ë†’ì€ AMRì„ ë³´ì˜€ëŠ”ë°, **ë§Œì•½ ICU í™˜ê²½ì„ ISSì²˜ëŸ¼ 'ì´ˆì²­ê²°(hyper-clean)'ë¡œ ë§Œë“¤ë©´ ì˜¤íˆë ¤ AMRì´ ë” ì•…í™”ë  ê°€ëŠ¥ì„±**ì€ ì—†ë‚˜ìš”? ì¦‰, moderate microbial diversityê°€ colonization resistanceë¥¼ ì œê³µí•˜ëŠ”ë°, ê³¼ë„í•œ ì‚´ê· ì´ ê·¸ ë³´í˜¸ë§‰ì„ ì œê±°í•˜ëŠ” ì—­ì„¤? í„°í‚¤ ë³‘ì›ì—ì„œ ì´ë¥¼ í…ŒìŠ¤íŠ¸í•œ natural experiment ì‚¬ë¡€ê°€ ìˆë‚˜ìš”?"

4. **[15% probability]** "Urban microbiomeì˜ 31ì¢… 'core microbes'ëŠ” ì¸ê°„ ê³µìƒê· ê³¼ ë‹¤ë¥´ë‹¤ê³  í•˜ì…¨ëŠ”ë°, **ì´ë“¤ì´ ì‹¤ì€ ì¸ê°„ microbiomeì˜ 'evolutionary reservoir'ì¼ ê°€ëŠ¥ì„±**ì€ìš”? ì¦‰, ë„ì‹œ í™˜ê²½ microbes â†’ ì¸ê°„ gut colonization â†’ adaptation â†’ new commensals? ë§Œì•½ ë§ë‹¤ë©´, ë„ì‹œ í™˜ê²½ manipulationì´ ì¸ê°„ microbiome evolutionì„ ê°€ì†í™”ì‹œí‚¬ ìˆ˜ ìˆê³ , AMR ì „íŒŒë¥¼ í†µì œí•˜ê¸°ë³´ë‹¤ëŠ” 'AMRì„ ê°€ì§„ beneficial microbes'ë¥¼ ì ê·¹ ë„ì…í•˜ëŠ” ì—­ë°œìƒ ì „ëµì€ ì–´ë–¨ê¹Œìš”?"

5. **[10% probability]** "pathfindRì˜ active subnetwork ê°œë…ì„ AMR ì§„í™”ì— ì ìš©í•˜ë©´, **'AMR gene network'ì—ë„ critical nodesê°€ ì¡´ì¬í•´ì„œ, ê·¸ê²ƒë§Œ íƒ€ê²Ÿí•˜ë©´ ì „ì²´ ë„¤íŠ¸ì›Œí¬ê°€ ë¶•ê´´í•  ê°€ëŠ¥ì„±**ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¹ì‹  ì—°êµ¬ëŠ” ëŒ€ë¶€ë¶„ individual gene ìˆ˜ì¤€ ë¶„ì„ì¸ë°, **AMR gene co-occurrence networkì˜ 'hub genes'ë‚˜ 'keystone resistance pathways'ë¥¼ ì‹ë³„í•œ ì ì´ ìˆë‚˜ìš”?** ë§Œì•½ ì—†ë‹¤ë©´, ì™œ pathfindR ê°œë°œìê°€ ì´ê±¸ ì•ˆ í–ˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤."

---

## ğŸ§© Category 2: Unexplored Intersections (ë¯¸íƒìƒ‰ êµì°¨ì )

### Question Set B: "The Temporal Dimension Missing"

**Context**: SEZERMANì˜ ëª¨ë“  ì—°êµ¬ëŠ” ì£¼ë¡œ cross-sectional ë˜ëŠ” ì§§ì€ longitudinalì…ë‹ˆë‹¤. ì§„í™”ì  ì‹œê°„ ì²™ë„ì™€ ìƒíƒœí•™ì  ì‹œê°„ ì²™ë„ì˜ êµì°¨ì ì´ ë¹„ì–´ ìˆìŠµë‹ˆë‹¤.

**5 Questions with Probabilities:**

1. **[35% probability]** "ë‹¹ì‹ ì˜ Urban microbiome studyëŠ” 3ë…„ê°„ ìƒ˜í”Œë§í–ˆì§€ë§Œ, **AMR ìœ ì „ìì˜ ì§„í™” ì†ë„(mutation accumulation rate)ì™€ ì „íŒŒ ì†ë„(HGT frequency)ë¥¼ ì‹¤ì œë¡œ ì¸¡ì •í•œ ì ì´ ìˆë‚˜ìš”?** ë§Œì•½ evolutionì´ ì˜ˆìƒë³´ë‹¤ 10ë°° ë¹ ë¥´ë‹¤ë©´, ìš°ë¦¬ì˜ surveillance ì£¼ê¸°ê°€ ë„ˆë¬´ ëŠë¦´ ìˆ˜ ìˆê³ , ë°˜ëŒ€ë¡œ 10ë°° ëŠë¦¬ë‹¤ë©´ ê³¼ì‰ ëŒ€ì‘ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. **í„°í‚¤ ë³‘ì›ì—ì„œ real-time evolution tracking (ë§¤ì¼ ìƒ˜í”Œë§ + WGS)ì„ í•´ë³¸ ì ì´ ìˆë‚˜ìš”?**"

2. **[25% probability]** "PANACEAëŠ” drug repurposingì„ ìœ„í•œ network proximityë¥¼ ê³„ì‚°í•˜ì§€ë§Œ, **ì‹œê°„ì  proximityëŠ” ê³ ë ¤í•˜ë‚˜ìš”?** ì¦‰, Drug Aê°€ pathway Xë¥¼ ì–µì œí•˜ì§€ë§Œ, bacteriaê°€ 24ì‹œê°„ ë‚´ì— alternative pathway Yë¡œ ìš°íšŒí•œë‹¤ë©´ ë¬´ìš©ì§€ë¬¼ì…ë‹ˆë‹¤. **Time-resolved network analysis (0hr, 6hr, 24hr, 72hr post-drug treatment RNA-seq)**ë¥¼ í†µí•´ 'escape pathways'ë¥¼ ë¯¸ë¦¬ ì˜ˆì¸¡í•˜ê³ , ê·¸ê²ƒê¹Œì§€ ë™ì‹œì— ì°¨ë‹¨í•˜ëŠ” combination therapyë¥¼ ì„¤ê³„í•  ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”?"

3. **[20% probability]** "S. pneumoniae ML ëª¨ë¸ì€ 95% accuracyë¡œ AMRì„ ì˜ˆì¸¡í•˜ì§€ë§Œ, **ì´ê±´ 'í˜„ì¬ ì‹œì ì˜ genotype â†’ í˜„ì¬ ì‹œì ì˜ phenotype' ì˜ˆì¸¡ì´ì£ . ë” ì–´ë ¤ìš´ ë¬¸ì œëŠ” 'í˜„ì¬ genotype â†’ ë¯¸ë˜ evolution trajectory'ì…ë‹ˆë‹¤.** ë‹¹ì‹ ì˜ ML modelì— temporal data (5ë…„ì¹˜ longitudinal strain collection)ë¥¼ ë„£ìœ¼ë©´, **'ì´ ê· ì£¼ê°€ 6ê°œì›” í›„ ì–´ë–¤ ìƒˆë¡œìš´ ë‚´ì„±ì„ íšë“í•  í™•ë¥ 'ì„ ì˜ˆì¸¡í•  ìˆ˜ ìˆë‚˜ìš”?** ì´ê²Œ ë˜ë©´ proactive interventionì´ ê°€ëŠ¥í•œë°, ì‹œë„í•´ë³¸ ì  ìˆë‚˜ìš”?"

4. **[12% probability]** "Microbiome-disease ì—°êµ¬ (migraine, epilepsy, etc.)ëŠ” ëŒ€ë¶€ë¶„ correlationì¸ë°, **causalityë¥¼ ì¦ëª…í•˜ë ¤ë©´ FMT (fecal microbiota transplant) ê°™ì€ interventionì´ í•„ìš”í•©ë‹ˆë‹¤.** ê·¸ëŸ°ë° ë‹¹ì‹ ì€ **AMR colonization resistanceì™€ microbiome diversityì˜ causal relationshipì„ í…ŒìŠ¤íŠ¸í•˜ê¸° ìœ„í•´ 'AMR-free microbiome transplant' ê°™ì€ ê±¸ ë™ë¬¼ ëª¨ë¸ì—ì„œ í•´ë³¸ ì ì´ ìˆë‚˜ìš”?** ì˜ˆë¥¼ ë“¤ì–´, high-diversity urban microbiomeì„ germ-free miceì— ì´ì‹ â†’ MDR bacteria challenge â†’ resistance ì¸¡ì •?"

5. **[8% probability]** "ë‹¹ì‹ ì˜ ëª¨ë“  ì—°êµ¬ê°€ bacteria ì¤‘ì‹¬ì¸ë°, **bacteriophages (íŒŒì§€)ëŠ” ì–´ë”” ê°”ë‚˜ìš”?** Urban/hospital metagenomeì—ëŠ” ìˆ˜ì¡° ê°œì˜ íŒŒì§€ê°€ ìˆì„ í…ë°, ì´ë“¤ì´ AMR ì „íŒŒ (transduction), ì–µì œ (phage therapy), ë˜ëŠ” evolution (CRISPR-Cas selection)ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì„ ì •ëŸ‰í™”í•œ ì ì´ ìˆë‚˜ìš”? **ë§Œì•½ íŒŒì§€ ë„¤íŠ¸ì›Œí¬ë¥¼ pathfindRë¡œ ë¶„ì„í•˜ë©´, 'keystone phages'ë¥¼ ì°¾ì•„ ì´ë¥¼ ì´ìš©í•œ AMR ì–µì œ ì „ëµ**ì„ ì„¤ê³„í•  ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”?"

---

## ğŸŒ Category 3: Scale Mismatches & Hidden Assumptions (ì²™ë„ ë¶ˆì¼ì¹˜ì™€ ìˆ¨ì€ ê°€ì •)

### Question Set C: "The Micro-Macro Gap"

**Context**: SEZERMANì€ molecular (genes) â†” ecological (urban/hospital) ì‚¬ì´ë¥¼ ì—°ê²°í•˜ì§€ë§Œ, individual organism ìˆ˜ì¤€ì´ ì¢…ì¢… ìƒëµë©ë‹ˆë‹¤.

**5 Questions with Probabilities:**

1. **[30% probability]** "pathfindRì€ 'active subnetwork'ë¥¼ ì°¾ì§€ë§Œ, ì´ê±´ **population-level average**ì£ . í•˜ì§€ë§Œ AMRì€ single-cell ìˆ˜ì¤€ì—ì„œ ë§¤ìš° heterogeneousí•©ë‹ˆë‹¤ (persister cells, phenotypic switching). **Single-cell RNA-seq ë°ì´í„°ë¥¼ pathfindRì— ë„£ìœ¼ë©´, cell-to-cell variationì´ ë„¤íŠ¸ì›Œí¬ êµ¬ì¡°ì— ì–´ë–¤ ì˜í–¥ì„ ì£¼ë‚˜ìš”?** í˜¹ì‹œ 'active subnetwork'ê°€ ì‹¤ì€ ì†Œìˆ˜ì˜ super-resistant cellsì—ì„œë§Œ ì‘ë™í•˜ê³ , ëŒ€ë¶€ë¶„ì˜ cellsëŠ” ë‹¤ë¥¸ ì „ëµì„ ì“°ëŠ” ê±´ ì•„ë‹ê¹Œìš”?"

2. **[25% probability]** "Urban microbiome ì—°êµ¬ëŠ” ì†ì¡ì´ í‘œë©´ì˜ DNAë¥¼ ë¶„ì„í•˜ì§€ë§Œ, **ê·¸ DNAì˜ ëŒ€ë¶€ë¶„ì´ 'ì£½ì€ ì„¸í¬' ë˜ëŠ” 'free DNA'ì—ì„œ ì˜¨ ê²ƒì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.** MetagenomicsëŠ” viable vs deadë¥¼ êµ¬ë¶„ ëª»í•˜ëŠ”ë°, **ë§Œì•½ AMR ìœ ì „ìì˜ 90%ê°€ ì‹¤ì œë¡œëŠ” non-viable sourceì—ì„œ ì™”ë‹¤ë©´, ìš°ë¦¬ê°€ overestimateí•˜ëŠ” ê±´ ì•„ë‹Œê°€ìš”?** RNA-seq (viability marker)ì™€ DNA-seqë¥¼ ë³‘í–‰í•œ ì ì´ ìˆë‚˜ìš”? ì°¨ì´ê°€ ì–¼ë§ˆë‚˜ ë‚¬ë‚˜ìš”?"

3. **[20% probability]** "ML ëª¨ë¸ (S. pneumoniae)ì€ k-mer featuresë¥¼ ì‚¬ìš©í•˜ëŠ”ë°, ì´ê±´ **sequence space representation**ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ AMR phenotypeì€ ê²°êµ­ **3D protein structure**ì™€ **protein-drug binding**ì— ì˜í•´ ê²°ì •ë©ë‹ˆë‹¤. **AlphaFold ê°™ì€ structure predictionì„ ML featureë¡œ ì¶”ê°€í•˜ë©´ accuracyê°€ 95%ì—ì„œ ì–¼ë§ˆë‚˜ ë” ì˜¬ë¼ê°ˆê¹Œìš”?** í˜¹ì‹œ ì‹œë„í•´ë´¤ëŠ”ë° ë³„ ì°¨ì´ ì—†ì—ˆë‚˜ìš”? ê·¸ë ‡ë‹¤ë©´ ê·¸ ì´ìœ ëŠ”?"

4. **[15% probability]** "Hospital AMR cartographyëŠ” ê³µê°„ ë¶„í¬ë¥¼ ë³´ì—¬ì£¼ì§€ë§Œ, **í™˜ì ì´ë™ ê²½ë¡œ (patient flow network)**ëŠ” ê³ ë ¤ ì•ˆ í–ˆì£ ? ì‹¤ì œë¡œëŠ” í™˜ìê°€ ICU â†’ ì¼ë°˜ë³‘ë™ â†’ ì™¸ë˜ë¡œ ì´ë™í•˜ë©´ì„œ AMRì„ ì „íŒŒí•  í…ë°, **í™˜ì ì´ë™ ë°ì´í„° (EMR)ì™€ í™˜ê²½ AMR ë°ì´í„°ë¥¼ ê²°í•©í•˜ë©´, 'ìŠˆí¼ì „íŒŒì ê²½ë¡œ(super-spreader routes)'ë¥¼ ì‹ë³„**í•  ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”? ì´ê²Œ ë˜ë©´ íŠ¹ì • ë³µë„ë‚˜ ì—˜ë¦¬ë² ì´í„°ë¥¼ ì§‘ì¤‘ ì‚´ê· í•˜ëŠ” targeted interventionì´ ê°€ëŠ¥í•œë°?"

5. **[10% probability]** "NICU microbiome studyì—ì„œ antibiotics â†’ dysbiosis â†’ AMR colonizationì„ ë³´ì˜€ëŠ”ë°, **ì´ê²Œ ì •ë§ antibioticsì˜ ì§ì ‘ íš¨ê³¼ì¸ì§€, ì•„ë‹ˆë©´ antibiotics â†’ infant immune suppression â†’ secondary effectì¸ì§€ êµ¬ë¶„í–ˆë‚˜ìš”?** ì¦‰, **germ-free miceì— antibioticsë§Œ ì£¼ë©´ (bacteria ì—†ì´ë„) immune systemì´ ë³€í•˜ë‚˜ìš”?** ë§Œì•½ ê·¸ë ‡ë‹¤ë©´, microbiome restorationë§Œìœ¼ë¡œëŠ” ë¶€ì¡±í•˜ê³  immune modulationë„ í•„ìš”í•  í…ë°, ì´ ê°€ëŠ¥ì„±ì„ íƒìƒ‰í•œ ì  ìˆë‚˜ìš”?"

---

## ğŸ”¬ Category 4: Methodological Blindspots (ë°©ë²•ë¡ ì  ë§¹ì )

### Question Set D: "What Your Tools Can't See"

**Context**: ê° ì—°êµ¬ ë°©ë²•ë¡ ì—ëŠ” ê³ ìœ ì˜ biasì™€ blind spotì´ ìˆìŠµë‹ˆë‹¤. SEZERMANì´ ì£¼ë¡œ ì“°ëŠ” ë°©ë²•ë“¤ì˜ í•œê³„ë¥¼ ë„ì „í•©ë‹ˆë‹¤.

**5 Questions with Probabilities:**

1. **[35% probability]** "MetagenomicsëŠ” 'what genes are there'ë¥¼ ë³´ì§€ë§Œ, **'how many copies per cell'ì€ ëª¨ë¦…ë‹ˆë‹¤.** AMR geneì´ 100% prevalenceë¼ê³  í•´ë„, ì‹¤ì œë¡œëŠ” 1 copy/cell vs 100 copies/cell (plasmid amplification)ì— ë”°ë¼ phenotypeì´ ì²œì§€ ì°¨ì´ì…ë‹ˆë‹¤. **qPCRì´ë‚˜ ddPCRë¡œ copy numberë¥¼ ì¸¡ì •í•´ë³¸ ì  ìˆë‚˜ìš”?** í˜¹ì‹œ measuringí–ˆëŠ”ë° DNA-seq abundanceì™€ correlationì´ ë‚®ì•˜ë‚˜ìš”? ê·¸ë ‡ë‹¤ë©´ metagenomics ê¸°ë°˜ AMR surveillanceì˜ ì‹ ë¢°ë„ëŠ”?"

2. **[25% probability]** "pathfindRì˜ PPI networkëŠ” ëŒ€ë¶€ë¶„ human ë˜ëŠ” model organisms (yeast, E. coli)ì—ì„œ ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¹ì‹ ì´ ì—°êµ¬í•˜ëŠ” ë§ì€ bacteria (Acinetobacter, Pseudomonas, C. auris)ëŠ” **PPI ë°ì´í„°ê°€ ê±°ì˜ ì—†ì£ .** ê·¸ëŸ¼ pathfindR ê²°ê³¼ëŠ” **'known PPIì— ê¸°ë°˜í•œ biased inference'**ì¼ í…ë°, ì´ ë¬¸ì œë¥¼ ì–´ë–»ê²Œ í•´ê²°í•˜ë‚˜ìš”? **AlphaFold-Multimerë¡œ de novo PPI prediction â†’ custom PPI network êµ¬ì¶•**ì„ ì‹œë„í•´ë³¸ ì  ìˆë‚˜ìš”?"

3. **[18% probability]** "ML model (k-mer + Random Forest)ì€ interpretabilityê°€ ë‚®ìŠµë‹ˆë‹¤. 'Black box'ì£ . ë‹¹ì‹ ì€ **ì–´ë–¤ k-merê°€ ì–´ë–¤ AMR mechanismê³¼ ì—°ê²°ë˜ëŠ”ì§€ mechanistic interpretation**ì„ í•œ ì ì´ ìˆë‚˜ìš”? ì˜ˆë¥¼ ë“¤ì–´, SHAP valuesë‚˜ attention mechanismsë¡œ 'important k-mers'ë¥¼ ë½‘ê³ , ê·¸ê²ƒë“¤ì´ ì‹¤ì œë¡œ efflux pumpë‚˜ penicillin-binding protein ê·¼ì²˜ì¸ì§€ í™•ì¸í–ˆë‚˜ìš”? ë§Œì•½ ì•ˆ í–ˆë‹¤ë©´, **í˜¹ì‹œ ëª¨ë¸ì´ spurious correlation (linkage disequilibrium ê°™ì€)ì— ì˜ì¡´í•˜ëŠ” ê±´ ì•„ë‹ê¹Œìš”?**"

4. **[12% probability]** "PANACEAëŠ” network proximityë¡œ drugë¥¼ prioritizeí•˜ì§€ë§Œ, **pharmacokinetics/pharmacodynamics (PK/PD)ëŠ” ì „í˜€ ê³ ë ¤ ì•ˆ í•©ë‹ˆë‹¤.** Drugê°€ in vitroì—ì„œ pathwayë¥¼ ì–µì œí•´ë„, ì‹¤ì œë¡œëŠ” target siteì— ë„ë‹¬ ëª»í•˜ê±°ë‚˜ (poor penetration), ë¹ ë¥´ê²Œ ëŒ€ì‚¬ë˜ê±°ë‚˜ (short half-life), ë…ì„±ì´ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. **PANACEAì— ADMET (absorption, distribution, metabolism, excretion, toxicity) filterë¥¼ ì¶”ê°€í•˜ë©´ false positive rateì´ ì–¼ë§ˆë‚˜ ì¤„ì–´ë“¤ê¹Œìš”?** ì‹œë„í•´ë³¸ ì  ìˆë‚˜ìš”?"

5. **[10% probability]** "ë‹¹ì‹ ì˜ ëª¨ë“  computational workì€ **'static snapshot' ê°€ì •**ì— ê¸°ë°˜í•©ë‹ˆë‹¤. NetworkëŠ” ê³ ì •ë˜ì–´ ìˆê³ , pathwayëŠ” í•­ìƒ ê°™ê³ , ML modelì€ training data ë¶„í¬ê°€ ìœ ì§€ëœë‹¤ê³  ê°€ì •í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ **biological systemsëŠ” adaptive**ì…ë‹ˆë‹¤. BacteriaëŠ” ë‹¹ì‹ ì˜ ì˜ˆì¸¡ì„ í”¼í•´ê°€ê³ , pathwayëŠ” rewireë˜ê³ , phenotypeì€ driftí•©ë‹ˆë‹¤. **Adversarial evolution** (bacteriaê°€ ë‹¹ì‹ ì˜ ML modelì„ 'ì†ì´ëŠ”' ë°©í–¥ìœ¼ë¡œ ì§„í™”)ì— ëŒ€í•œ robustnessë¥¼ í…ŒìŠ¤íŠ¸í•œ ì  ìˆë‚˜ìš”? ì˜ˆë¥¼ ë“¤ì–´, 'ë§Œì•½ bacteriaê°€ k-mer signatureë¥¼ ë°”ê¾¸ì§€ ì•Šê³ ë„ resistanceë¥¼ ì–»ëŠ”ë‹¤ë©´?' ê°™ì€ ì‹œë‚˜ë¦¬ì˜¤?"

---

## ğŸ’¥ Category 5: Radical Alternatives & Paradigm Shifts (ê¸‰ì§„ì  ëŒ€ì•ˆê³¼ íŒ¨ëŸ¬ë‹¤ì„ ì „í™˜)

### Question Set E: "What If Everything Is Wrong?"

**Context**: ê·¼ë³¸ì  ê°€ì •ë“¤ì„ ë’¤ì§‘ì–´ì„œ, ì™„ì „íˆ ë‹¤ë¥¸ ì—°êµ¬ ë°©í–¥ì„ ì œì‹œí•©ë‹ˆë‹¤.

**5 Questions with Probabilities:**

1. **[28% probability]** "ë‹¹ì‹ ì˜ ëª¨ë“  ì—°êµ¬ëŠ” 'AMRì€ ë¬¸ì œë‹¤, ì¤„ì—¬ì•¼ í•œë‹¤'ëŠ” ì „ì œì—ì„œ ì¶œë°œí•©ë‹ˆë‹¤. í•˜ì§€ë§Œ **evolutionary perspectiveì—ì„œ ë³´ë©´, AMRì€ bacteriaì˜ ì •ìƒì ì¸ adaptive response**ì…ë‹ˆë‹¤. ë§Œì•½ ìš°ë¦¬ê°€ AMRì„ ì—†ì• ë ¤ê³  í•˜ì§€ ë§ê³ , **'harmless AMR'ê³¼ 'harmful AMR'ì„ êµ¬ë¶„í•´ì„œ, harmless AMRì„ ì¦í­ì‹œì¼œ harmful AMRì„ ê²½ìŸì ìœ¼ë¡œ ì–µì œí•˜ëŠ” ì „ëµ**ì€ ì–´ë–¨ê¹Œìš”? ì´ëŸ° 'AMR dilution strategy'ë¥¼ ê³ ë ¤í•´ë³¸ ì  ìˆë‚˜ìš”? ì˜ˆë¥¼ ë“¤ì–´, non-pathogenic E. coli with AMR genesë¥¼ gutì— ì´ì‹í•´ì„œ, pathogenic MRSA colonizationì„ ë°©ì–´?"

2. **[24% probability]** "Urban microbiome ì—°êµ¬ëŠ” 'AMR surveillance'ì— ì´ˆì ì„ ë§ì¶”ì§€ë§Œ, **reverse engineeringìœ¼ë¡œ 'ìì—°ì ìœ¼ë¡œ AMRì´ ë‚®ì€ ë„ì‹œ'ì˜ íŠ¹ì„±ì„ í•™ìŠµí•´ì„œ, ê·¸ê±¸ ë‹¤ë¥¸ ë„ì‹œì— ì ìš©í•˜ëŠ” 'AMR-resistant city design'**ì€ ê°€ëŠ¥í• ê¹Œìš”? ì˜ˆë¥¼ ë“¤ì–´, ì„œìš¸ì´ ë‰´ìš•ë³´ë‹¤ AMRì´ ë‚®ë‹¤ë©´, ê·¸ ì´ìœ ê°€ ì§€í•˜ì²  í™˜í’ ì‹œìŠ¤í…œ, ìŠµë„, ì²­ì†Œ í”„ë¡œí† ì½œ, ìŠ¹ê° ë°€ë„ ì¤‘ ë­”ì§€ ì•Œì•„ë‚´ì„œ, **'AMR-optimized urban planning'**ì„ ì œì•ˆí•  ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”?"

3. **[20% probability]** "pathfindRê³¼ PANACEAëŠ” ëª¨ë‘ **'ê³ ì¹˜ëŠ”(fix)' ì ‘ê·¼ë²•**ì…ë‹ˆë‹¤. Pathwayë¥¼ ì–µì œí•˜ê³ , drugë¥¼ ì°¾ê³ , resistanceë¥¼ ë§‰ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ **'ë°›ì•„ë“¤ì´ëŠ”(accept)' ì ‘ê·¼ë²•**ì€ ì–´ë–¨ê¹Œìš”? ì¦‰, **post-antibiotic eraë¥¼ ê¸°ì •ì‚¬ì‹¤ë¡œ ë³´ê³ , 'AMRì´ ìˆëŠ” ìƒíƒœì—ì„œë„ ê°ì—¼ì„ í†µì œí•˜ëŠ” ë°©ë²•'**ì— ì§‘ì¤‘í•˜ëŠ” ê²ë‹ˆë‹¤. ì˜ˆ: immune boosting, phage therapy, anti-virulence drugs, microbiome fortification. ë‹¹ì‹ ì˜ network analysisë¥¼ ì´ëŸ° ë°©í–¥ìœ¼ë¡œ ëŒë¦¬ë©´, **'resistance geneì„ ê°€ì¡Œì§€ë§Œ virulenceë¥¼ ìƒì€ mutants'ë¥¼ ì„ íƒì ìœ¼ë¡œ ì¦í­**ì‹œí‚¤ëŠ” ì „ëµì„ ì°¾ì„ ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”?"

4. **[16% probability]** "ë‹¹ì‹ ì˜ computational tools (pathfindR, PANACEA, ML)ëŠ” ëª¨ë‘ **post-hoc analysis**ì…ë‹ˆë‹¤. ë°ì´í„°ë¥¼ ëª¨ì€ í›„ ë¶„ì„í•˜ì£ . í•˜ì§€ë§Œ **active learningì´ë‚˜ reinforcement learning**ì„ ì“°ë©´, **ì‹¤í—˜ ì„¤ê³„ ìì²´ë¥¼ optimize**í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜ˆ: 'ML modelì´ ë¶ˆí™•ì‹¤í•œ ì˜ì—­ì˜ ê· ì£¼ë¥¼ ìš°ì„  sequencing' â†’ ëª¨ë¸ ê°œì„  â†’ ë°˜ë³µ. **Closed-loop automated lab (robot + ML)**ì„ êµ¬ì¶•í•˜ë©´, ë‹¹ì‹ ì´ 10ë…„ ê±¸ë¦´ ì¼ì„ 1ë…„ì— ëë‚¼ ìˆ˜ ìˆëŠ”ë°, ì´ëŸ° infrastructure êµ¬ì¶•ì„ ê³ ë ¤í•´ë³¸ ì  ìˆë‚˜ìš”? í„°í‚¤ì— ì´ëŸ° facilityê°€ ìˆë‚˜ìš”?"

5. **[12% probability]** "ëª¨ë“  AMR ì—°êµ¬ëŠ” **'bacteria ê´€ì '**ì…ë‹ˆë‹¤. ì–´ë–¤ ìœ ì „ì, ì–´ë–¤ pathway, ì–´ë–¤ ì§„í™”. í•˜ì§€ë§Œ **'antibiotic ê´€ì '**ì—ì„œ ë³´ë©´ ì–´ë–¨ê¹Œìš”? ì¦‰, **'ì™œ ì–´ë–¤ í•­ìƒì œëŠ” resistanceê°€ ë¹ ë¥´ê²Œ ìƒê¸°ê³ , ì–´ë–¤ ê±´ ëŠë¦´ê¹Œ?'** ë¥¼ systematicí•˜ê²Œ ë¹„êµí•œ ì—°êµ¬ëŠ” ê±°ì˜ ì—†ìŠµë‹ˆë‹¤. **Antibiotic chemical structure â†’ resistance evolution rate**ë¥¼ ì˜ˆì¸¡í•˜ëŠ” ML modelì„ ë§Œë“¤ë©´, **ì‹ ì•½ ê°œë°œ ì´ˆê¸°ì— 'resistance-proof design'**ì„ í•  ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”? ì´ëŸ° 'reverse pharmacology' ì—°êµ¬ì— ê´€ì‹¬ ìˆë‚˜ìš”?"

---

## ğŸ¯ Meta-Question: Synthesis Across Categories

**The Ultimate Provocative Question [100% probability of making him think]:**

> "ë‹¹ì‹ ì€ ì§€ë‚œ 10ë…„ê°„ **Urban metagenomics (Cell)**, **Hospital mapping (Nature Med)**, **pathfindR (Frontiers)**, **PANACEA (Bioinformatics)**, **ML for AMR (Frontiers Antibiotics)**, **Microbiome-disease (multiple journals)** ë“± ì—„ì²­ë‚˜ê²Œ ë‹¤ì–‘í•œ ë¶„ì•¼ì—ì„œ ì—°êµ¬í•´ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì†”ì§íˆ ë§í•´ì„œ, **ì´ ëª¨ë“  ì—°êµ¬ê°€ í•˜ë‚˜ì˜ í†µí•©ëœ frameworkë¡œ ì—°ê²°ë˜ëŠ”ê°€ìš”?**
>
> ì•„ë‹ˆë©´ ê°ê°ì´ ë…ë¦½ì ì¸ í”„ë¡œì íŠ¸ì¸ê°€ìš”?
>
> ë§Œì•½ í•˜ë‚˜ì˜ 'Sezerman's Unified Theory of AMR Ecology'ë¥¼ ì“´ë‹¤ë©´, **í•µì‹¬ ì›ë¦¬ 3ê°€ì§€ëŠ” ë­”ê°€ìš”?**
>
> ê·¸ë¦¬ê³  **ì´ frameworkì˜ ê°€ì¥ í° missing pieceëŠ” ë­”ê°€ìš”?**
>
> ì˜ˆë¥¼ ë“¤ì–´, ì œê°€ ë³´ê¸°ì—” ë‹¹ì‹ ì€ **'spatial' (urban/hospital)**, **'molecular' (genes/pathways)**, **'computational' (ML/network)**ì€ ë‹¤ë£¨ì§€ë§Œ, **'temporal evolution'**ê³¼ **'individual-level stochasticity'**ê°€ ì•½í•œ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë™ì˜í•˜ì‹œë‚˜ìš”?
>
> ê·¸ë¦¬ê³  ë§Œì•½ **10ì–µì› budgetê³¼ 5ë…„ ì‹œê°„**ì„ ì¤€ë‹¤ë©´, **'missing piece'ë¥¼ ì±„ìš°ê¸° ìœ„í•œ í”„ë¡œì íŠ¸ë¥¼ ì„¤ê³„í•œë‹¤ë©´** ì–´ë–¤ ê±¸ í•˜ì‹œê² ì–´ìš”?"

---

## ğŸ“Š Verbalized Probability Summary

### Overall Question Distribution by Type:

- **Paradoxes & Contradictions**: 5 questions (ê°•ë„ â˜…â˜…â˜…â˜…â˜…)
  - ISS vs Urban microbiome contradiction
  - AMR as stress response vs antibiotic response
  - Hyper-clean environment paradox
  - Urban microbes as evolutionary reservoir
  - AMR gene network hub identification

- **Unexplored Intersections**: 5 questions (ê°•ë„ â˜…â˜…â˜…â˜…â˜†)
  - Real-time evolution tracking (temporal dimension)
  - Time-resolved network analysis (escape pathways)
  - Evolution trajectory prediction (ML + temporal)
  - Causality testing (FMT experiments)
  - Bacteriophage network (missing layer)

- **Scale Mismatches**: 5 questions (ê°•ë„ â˜…â˜…â˜…â˜…â˜†)
  - Single-cell heterogeneity in pathfindR
  - Viable vs dead DNA (metagenomics bias)
  - Protein structure features in ML
  - Patient flow network integration
  - Antibiotics' immune effects vs microbiome effects

- **Methodological Blindspots**: 5 questions (ê°•ë„ â˜…â˜…â˜…â˜…â˜…)
  - Copy number quantification (qPCR validation)
  - De novo PPI prediction (AlphaFold-Multimer)
  - ML interpretability (SHAP, mechanistic)
  - PK/PD integration in PANACEA
  - Adversarial evolution robustness

- **Radical Alternatives**: 5 questions (ê°•ë„ â˜…â˜…â˜…â˜…â˜…)
  - AMR dilution strategy (harmless vs harmful)
  - AMR-resistant city design (urban planning)
  - Post-antibiotic acceptance paradigm
  - Active learning + automated lab
  - Reverse pharmacology (antibiotic design)

### Expected Impact:

- **High impact** (70% probability): Questions revealing fundamental gaps that could spawn new research directions
- **Medium impact** (25% probability): Questions prompting defensive responses but leading to productive discussions
- **Low impact** (5% probability): Questions dismissed as impractical but planting seeds for future consideration

---

## ğŸ¬ Deployment Strategy

### When to Ask These Questions:

**âŒ DO NOT ask during formal Q&A**
- Too long, too confrontational
- Disrupts seminar flow
- Makes you look aggressive

**âœ… DO ask during 1:1 conversation** (ê°•ì—° í›„ or coffee meeting)
- Shows deep engagement
- Opens collaborative discussions
- Reveals your creative thinking

**âœ… BEST: Include in follow-up email**
- Subject: "Provocative questions inspired by your seminar"
- Pick 2-3 from different categories
- Frame as "research brainstorming" not criticism
- Propose collaboration to address these gaps

### How to Frame:

**Bad framing:**
"Your research has a fundamental flaw..."

**Good framing:**
"Your ISS and Urban microbiome findings create a fascinating paradox that made me think... [question]. This could be a great follow-up study. Would you be interested in exploring this together?"

### Expected Responses:

1. **"That's a great question, we actually tried that but..."** â†’ Dig deeper into unpublished data
2. **"Hmm, I never thought about it that way..."** â†’ Collaboration opportunity!
3. **"That's beyond the scope of our study..."** â†’ Push gently: "But wouldn't it be the next logical step?"
4. **"There are technical limitations..."** â†’ Offer Korea Pasteur resources to overcome them

---

## ğŸš€ Integration with Korea Pasteur Collaboration

### Use These Questions to Position Proposals:

Instead of generic "let's collaborate on Seoul Metro AMR", use:

> "Your Urban microbiome work revealed city-specific AMR patterns, but the **temporal evolution rate** remains unmeasured. What if we leverage Seoul Metro's **IoT-enabled real-time sampling system** (Korea has excellent infrastructure) to create the world's first **'living AMR map'** with daily updates? This would let us test whether AMR evolution follows **predictable trajectories** or chaotic jumps. **We could answer your 'temporal dimension' question while creating unprecedented surveillance capacity.**"

### Gaps â†’ Projects Mapping:

| Research Gap | Korea Pasteur Strength | Proposed Collaboration |
|--------------|------------------------|------------------------|
| Temporal evolution tracking | Access to hospital EMR + longitudinal cohorts | Real-time hospital AMR evolution study |
| Causality testing (FMT) | Animal facility + GF mice | Microbiome-AMR causality experiments |
| Single-cell AMR heterogeneity | scRNA-seq facility | Persister cell network analysis |
| PK/PD integration in PANACEA | Clinical trial infrastructure | PANACEA validation + optimization |
| Bacteriophage network | Phage therapy interest in Korea | Phage-bacteria-AMR tri-network analysis |
| AMR-resistant city design | Smart city initiatives (Seoul, Songdo) | Urban planning + AMR prevention |

---

## ğŸ“ êµí›ˆ (Lessons from Verbalized Sampling)

### What Made These Questions Different:

1. **Avoided obvious next steps**: Everyone will ask "can we use your method for X?"
2. **Exposed hidden assumptions**: "AMR is bad" â†’ questioned
3. **Connected distant fields**: ISS + ICU, Urban planning + AMR, Phages + Networks
4. **Challenged paradigms**: "Fix AMR" â†’ "Live with AMR"
5. **Focused on measurement gaps**: What tools can't currently see

### Why They're Provocative:

- **Force re-examination of foundations** (e.g., "Is AMR really about antibiotics?")
- **Reveal unexplored synergies** (e.g., pathfindR + phage networks)
- **Highlight methodological blindspots** (e.g., viable vs dead DNA)
- **Propose radical alternatives** (e.g., AMR dilution instead of elimination)
- **Demand quantification of assumptions** (e.g., "What's the sweet spot stress level?")

### How to Generate Your Own:

Using Verbalized Sampling principles:

```
Step 1: List 5 assumptions in the research
Step 2: For each, ask "What if the opposite is true?"
Step 3: Identify 3 missing scales (spatial, temporal, organizational)
Step 4: Find 2 methodological blind spots
Step 5: Propose 1 radical paradigm shift
Step 6: Assign probabilities based on feasibility + impact
Step 7: Select top 5 that maximize diversity
```

---

## ğŸ“Œ Final Note

ì´ ì§ˆë¬¸ë“¤ì€ **ë¹„íŒ(criticism)**ì´ ì•„ë‹ˆë¼ **í™•ì¥(expansion)**ì…ë‹ˆë‹¤. SEZERMANì˜ ì—°êµ¬ê°€ excellentí•˜ê¸° ë•Œë¬¸ì—, ê·¸ ê²½ê³„ë¥¼ ë„˜ì–´ì„œëŠ” ì§ˆë¬¸ë“¤ì´ ì˜ë¯¸ìˆìŠµë‹ˆë‹¤.

ë»”í•œ ì§ˆë¬¸ ("Can you apply pathfindR to my data?")ì€ ëˆ„êµ¬ë‚˜ í•  ìˆ˜ ìˆì§€ë§Œ, ì´ëŸ° ì§ˆë¬¸ë“¤ì€ **"I understand your work deeply enough to see what's NOT there"**ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.

**Verbalized Samplingì˜ í•µì‹¬**: Mode collapseë¥¼ í”¼í•˜ê³ , typicality biasë¥¼ ê·¹ë³µí•˜ë©°, ì§„ì§œ ì°½ì˜ì  ê³µê°„ì„ íƒìƒ‰í•˜ëŠ” ê²ƒ.

ê°•ì—° í›„ "í¥ë¯¸ë¡œìš´ ì§ˆë¬¸"ì´ ì•„ë‹ˆë¼ **"í•¨ê»˜ ì—°êµ¬í•˜ê³  ì‹¶ì€ ì‚¬ëŒ"**ìœ¼ë¡œ ê¸°ì–µë˜ëŠ” ê²Œ ëª©í‘œì…ë‹ˆë‹¤.

---

**Ready for deployment! ğŸš€**
